Correspondence

Cannabis-based products for medicinal use: assessing the impact

A framework for the assessment of the impact of rescheduling cannabis-based products for medicinal use (CBPMs).

• From: Advisory Council on the Misuse of Drugs
• Published: 23 December 2019

Documents

Framework for the assessment of the impact of rescheduling cannabis-based products for medicinal use

PDF, 577 KB, 16 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

In a February 2019 commission, the Home Secretary asked the ACMD to:

provide an outline for an assessment framework. This should set out how the ACMD will assess the various impacts of rescheduling cannabis-based products for medicinal use to Schedule 2 under the 2001 Regulations, and the data sources (including those provided by the Home Office and DHSC) the ACMD will use by November 2019?

The ACMD are pleased to provide this outline assessment framework, and will use it to provide a full report assessing the impacts of the rescheduling of CBPMs to Schedule 2, by November 2020.

We are aware these publications may have accessibility issues. We are reviewing them so that we can fix these.

Read more about our accessible documents policy.

Published 23 December 2019